NASDAQ:AVRO - Avrobio News Headlines

$14.74
+0.13 (+0.89 %)
(As of 06/20/2019 01:01 PM ET)
Today's Range
$14.51
Now: $14.7450
$15.02
50-Day Range
$13.35
MA: $16.30
$20.68
52-Week Range
$11.85
Now: $14.7450
$53.70
Volume103,111 shs
Average Volume134,551 shs
Market Capitalization$356.09 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Avrobio (NASDAQ AVRO) News Headlines

Source:
DateHeadline
Avrobio Inc (NASDAQ:AVRO) Expected to Post Earnings of -$0.76 Per ShareAvrobio Inc (NASDAQ:AVRO) Expected to Post Earnings of -$0.76 Per Share
www.americanbankingnews.com - June 20 at 12:18 PM
Avrobio Inc (NASDAQ:AVRO) Given Consensus Recommendation of "Buy" by BrokeragesAvrobio Inc (NASDAQ:AVRO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 19 at 6:37 AM
 Brokerages Anticipate Avrobio Inc (AVRO) Will Post Earnings of -$0.75 Per Share Brokerages Anticipate Avrobio Inc (AVRO) Will Post Earnings of -$0.75 Per Share
www.americanbankingnews.com - May 28 at 4:22 PM
Here’s What Hedge Funds Think About AVROBIO, Inc. (AVRO)Here’s What Hedge Funds Think About AVROBIO, Inc. (AVRO)
finance.yahoo.com - May 13 at 11:59 AM
AVROBIO, Inc. Reports First Quarter 2019 Financial Results and Provides Business UpdateAVROBIO, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
finance.yahoo.com - May 13 at 11:59 AM
BioBridge Global adds two industry leaders to Regenerative Medicine Advisory BoardBioBridge Global adds two industry leaders to Regenerative Medicine Advisory Board
www.globenewswire.com - May 6 at 11:45 AM
FDA OKs AVROBIOs IND for AVR-RD-01 for FabryFDA OKs AVROBIO's IND for AVR-RD-01 for Fabry
seekingalpha.com - April 30 at 11:39 AM
FDA clears AVROBIOs IND for AVR-RD-01 for the treatment of fabry diseaseFDA clears AVROBIO's IND for AVR-RD-01 for the treatment of fabry disease
seekingalpha.com - April 29 at 11:38 AM
AVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application for AVR-RD-01 Gene Therapy for the Treatment of Fabry DiseaseAVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application for AVR-RD-01 Gene Therapy for the Treatment of Fabry Disease
finance.yahoo.com - April 29 at 11:38 AM
AVROBIO Highlights the plato™ Platform and Gaucher and Cystinosis Programs at the 2019 Annual Meeting of the American Society of Gene and Cell TherapyAVROBIO Highlights the plato™ Platform and Gaucher and Cystinosis Programs at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy
finance.yahoo.com - April 27 at 11:35 AM
Janney likes AVROBIO and Amicus in premarket analyst actionJanney likes AVROBIO and Amicus in premarket analyst action
seekingalpha.com - April 5 at 3:53 PM
Biotech, in motion: Demand for life science execs fuels game of musical chairsBiotech, in motion: Demand for life science execs fuels game of musical chairs
www.bizjournals.com - April 4 at 4:00 PM
AVROBIO, Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business UpdateAVROBIO, Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update
www.marketwatch.com - March 25 at 12:13 PM
AVROBIO, Inc. Estimate MomentumAVROBIO, Inc. Estimate Momentum
www.nasdaq.com - March 18 at 4:00 PM
AVROBIO, Inc. to Present at the Cowen and Company 39th Annual Health Care ConferenceAVROBIO, Inc. to Present at the Cowen and Company 39th Annual Health Care Conference
finance.yahoo.com - March 5 at 3:52 PM
AVROBIO updates on gene therapy for FabryAVROBIO updates on gene therapy for Fabry
seekingalpha.com - February 6 at 12:12 PM
BRIEF-Avrobio Announces Updated Clinical Data From Ongoing Phase 1 And Phase 2 Studies For AVR-RD-01 Gene TherapyBRIEF-Avrobio Announces Updated Clinical Data From Ongoing Phase 1 And Phase 2 Studies For AVR-RD-01 Gene Therapy
www.msn.com - February 6 at 12:12 PM
Investors Are Undervaluing AVROBIO, Inc. (NASDAQ:AVRO) By 46.82%Investors Are Undervaluing AVROBIO, Inc. (NASDAQ:AVRO) By 46.82%
finance.yahoo.com - February 6 at 12:12 PM
AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry DiseaseAVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease
finance.yahoo.com - February 6 at 12:12 PM
AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019
finance.yahoo.com - February 1 at 12:03 PM
FDA accepts AVROBIOs IND for AVR-RD-04FDA accepts AVROBIO's IND for AVR-RD-04
seekingalpha.com - January 18 at 2:19 PM
AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for CystinosisAVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis
finance.yahoo.com - January 18 at 2:19 PM
AVROBIO Enters Oversold TerritoryAVROBIO Enters Oversold Territory
finance.yahoo.com - January 18 at 2:19 PM
AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019
finance.yahoo.com - January 17 at 12:48 PM
AVROBIO Inc.AVROBIO Inc.
www.barrons.com - January 8 at 3:40 PM
AVROBIO, Inc. Appoints Philip J. Vickers to its Board of DirectorsAVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors
finance.yahoo.com - January 7 at 10:59 AM
AVROBIO, Inc. Added to NASDAQ Biotechnology IndexAVROBIO, Inc. Added to NASDAQ Biotechnology Index
finance.yahoo.com - December 21 at 3:28 PM
Should You Avoid AVROBIO, Inc. (AVRO)?Should You Avoid AVROBIO, Inc. (AVRO)?
finance.yahoo.com - December 21 at 9:46 AM
FDA grants Orphan-Drug designation to AVROBIOs AVR RD 01FDA grants Orphan-Drug designation to AVROBIO's AVR RD 01
seekingalpha.com - December 19 at 9:57 AM
AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR RD 01 for the Treatment of Fabry DiseaseAVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR RD 01 for the Treatment of Fabry Disease
finance.yahoo.com - December 19 at 9:57 AM
AVROBIO announces four senior management hiresAVROBIO announces four senior management hires
seekingalpha.com - December 18 at 10:02 AM
BRIEF-AVROBIO Inc Appoints Erik Ostrowski As Chief Financial OfficerBRIEF-AVROBIO Inc Appoints Erik Ostrowski As Chief Financial Officer
www.msn.com - December 18 at 10:02 AM
AVROBIO, Inc. Expands and Strengthens Leadership Team with Four Senior Management HiresAVROBIO, Inc. Expands and Strengthens Leadership Team with Four Senior Management Hires
finance.yahoo.com - December 18 at 10:02 AM
AVROBIO, Inc. Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)AVROBIO, Inc. Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - December 18 at 10:02 AM
Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO — Research Highlights Growth, Revenue, and Consolidated ResultsAnalysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - November 21 at 8:39 AM
AVROBIO, Inc. Reports Third Quarter 2018 Financial Results and Provides Business UpdateAVROBIO, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update
finance.yahoo.com - November 13 at 8:10 AM
AVROBIO, Inc. to Present at Chardans 2nd Annual Genetic Medicines ConferenceAVROBIO, Inc. to Present at Chardan's 2nd Annual Genetic Medicines Conference
finance.yahoo.com - October 5 at 7:21 AM
AVROBIO, Inc (AVRO) Reports No Objection to Clinical Trial Application from Health Canada for AVR-RD-02 Gene Therapy for Gaucher DiseaseAVROBIO, Inc (AVRO) Reports 'No Objection' to Clinical Trial Application from Health Canada for AVR-RD-02 Gene Therapy for Gaucher Disease
www.streetinsider.com - October 2 at 7:33 AM
AVROBIO down 15% premarket following announcement of trial data on Fabry gene therapyAVROBIO down 15% premarket following announcement of trial data on Fabry gene therapy
seekingalpha.com - October 1 at 3:19 PM
AVROBIO Announces Updated Clinical Data for AVR-RD-01 Gene Therapy in Fabry DiseaseAVROBIO Announces Updated Clinical Data for AVR-RD-01 Gene Therapy in Fabry Disease
finance.yahoo.com - October 1 at 7:22 AM
AVROBIO Receives No Objection to Clinical Trial Application from Health Canada for AVR-RD-02 Gene Therapy for Gaucher DiseaseAVROBIO Receives No Objection to Clinical Trial Application from Health Canada for AVR-RD-02 Gene Therapy for Gaucher Disease
finance.yahoo.com - October 1 at 7:22 AM
AVROBIO builds on successful IPO, up 9%AVROBIO builds on successful IPO, up 9%
seekingalpha.com - September 20 at 3:18 PM
AVROBIO, Inc. to Present at Upcoming Investor ConferencesAVROBIO, Inc. to Present at Upcoming Investor Conferences
globenewswire.com - August 28 at 3:17 PM
AVROBIO, Inc. Reports Second Quarter 2018 Financial Results and Provides Business UpdateAVROBIO, Inc. Reports Second Quarter 2018 Financial Results and Provides Business Update
finance.yahoo.com - August 9 at 3:16 PM
AVROBIO, Inc. to Present at the 2018 Wedbush PacGrow Healthcare ConferenceAVROBIO, Inc. to Present at the 2018 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 8 at 3:16 PM
[$$] Five Drug Startups Reveal Plans to Join Blitz of Biotech IPOs[$$] Five Drug Startups Reveal Plans to Join Blitz of Biotech IPOs
finance.yahoo.com - July 16 at 4:39 PM
AVROBIO, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters Overallotment OptionAVROBIO, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Overallotment Option
finance.yahoo.com - July 16 at 4:39 PM
AVROBIO, Inc. Appoints Phillip B. Donenberg to its Board of DirectorsAVROBIO, Inc. Appoints Phillip B. Donenberg to its Board of Directors
finance.yahoo.com - July 16 at 4:39 PM
Newly Public Gene Therapy Biotech Avrobio Picks Up 2 Sell-Side BullsNewly Public Gene Therapy Biotech Avrobio Picks Up 2 Sell-Side Bulls
finance.yahoo.com - July 16 at 4:39 PM
This page was last updated on 6/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel